An analyst from Ladenburg Thalmann initiated coverage of Sonnet Biotherapeutics Holdings (NASDAQ: SONN) at 'buy' with a price target of $7.0000. Prior to this rating, Sonnet...
Sonnet BioTherapeutics Holdings, Inc., (SONN) a clinical-stage company developing targeted immunotherapeutic drugs for cancer, provided a fiscal year 2023 business overview."As has been our...
Sonnet BioTherapeutics Holdings, Inc. (SONN) ("we," "us," "our," "Sonnet" or the "Company"), a clinical-stage company developing innovative targeted biologic drugs, today announced the...
Sonnet BioTherapeutics Holdings, Inc. (SONN) announced data from two radiolabeling studies that validate the tumor targeting attributes associated with albumin binding by the FHAB...
Sonnet BioTherapeutics Holdings, Inc., (SONN) announced today that it has received formal notice from the Listing Qualifications staff of The Nasdaq Stock Market indicating that Sonnet has...
Sonnet BioTherapeutics Holdings, Inc. (SONN) ("Sonnet" or the "Company"), a biopharmaceutical company developing innovative targeted biologic drugs, announced today that it will effect a...
An analyst from EF Hutton initiated coverage of Sonnet Biotherapeutics Holdings (NASDAQ: SONN) at 'buy' with a price target of $6.70. Prior to this rating, Sonnet Biotherapeutics Holdings...
Sonnet BioTherapeutics Holdings, Inc., (NASDAQ:SONN) a clinical-stage company developing targeted immunotherapeutic drugs, announced today that the IND for SB221 (NCT05756907), the Phase...
Investing.com - Sonnet Biotherapeutics Holdings (NASDAQ: SONN) reported second quarter EPS of $-0.1300, $0.16 better than the analyst estimate of $-0.2900. Revenue for the quarter came in at...
Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) today announced that it has entered into a definitive agreement with a single institutional investor for the purchase and sale of an...
Clinical trial was approved by the Bellberry Human Research Ethics Committee (HREC) in AustraliaThe combination of Sonnet's SON-1010 and Roche's atezolizumab (Tecentriq�) will be evaluated...
An analyst from EF Hutton initiated coverage of Sonnet Biotherapeutics Holdings (NASDAQ: SONN) at 'buy' with a price target of $6.70. Prior to this rating, Sonnet Biotherapeutics Holdings...
Investing.com - Sonnet Biotherapeutics Holdings (NASDAQ: SONN) reported first quarter EPS of $-0.3400, $0.16 better than the analyst estimate of $-0.4950. Revenue for the quarter came in at...
Sonnet BioTherapeutics Holdings, Inc. (SONN) reported Q1 EPS of ($0.80), $0.33 better than the analyst estimate of ($1.13). Revenue for the quarter came in at $40 thousand versus the...
Investing.com - Sonnet Biotherapeutics Holdings (NASDAQ: SONN) reported fourth quarter EPS of $-0.8000, $0.33 better than the analyst estimate of $-1.1300. Revenue for the quarter came in at...
Investing.com - Sonnet Biotherapeutics Holdings reported on Wednesday third quarter {{erl-31041||earnings that beat analysts' forecasts and revenue that topped expectations. Sonnet...
Investing.com – U.S. equities were higher at the close on Wednesday, as gains in the Technology, Consumer Services and Financials sectors propelled shares higher. At the close in NYSE, the...
Investing.com – U.S. equities were higher at the close on Friday, as gains in the Technology, Utilities and Consumer Services sectors propelled shares higher. At the close in NYSE, the Dow...
Investing.com – U.S. equities were mixed at the close on Thursday, as gains in the Technology, Healthcare and Utilities sectors propelled shares higher while losses in the Oil & Gas, Basic...
Investing.com – U.S. equities were higher at the close on Monday, as gains in the Oil & Gas, Basic Materials and Financials sectors propelled shares higher. At the close in NYSE, the Dow...
Investing.com – U.S. equities were higher at the close on Tuesday, as gains in the Technology, Consumer Goods and Consumer Services sectors propelled shares higher. At the close in NYSE,...
Investing.com – U.S. equities were lower at the close on Friday, as losses in the Oil & Gas, Industrials and Basic Materials sectors propelled shares lower. At the close in NYSE, the Dow...
Investing.com – U.S. equities were higher at the close on Thursday, as gains in the Utilities, Telecoms and Healthcare sectors propelled shares higher. At the close in NYSE, the Dow Jones...
Investing.com – U.S. equities were higher at the close on Wednesday, as gains in the Oil & Gas, Technology and Healthcare sectors propelled shares higher. At the close in NYSE, the Dow...
Investing.com – U.S. equities were higher at the close on Tuesday, as gains in the Oil & Gas, Technology and Basic Materials sectors propelled shares higher. At the close in NYSE, the Dow...
Investing.com – U.S. equities were higher at the close on Friday, as gains in the Oil & Gas, Basic Materials and Telecoms sectors propelled shares higher. At the close in NYSE, the Dow...
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data. Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
